AquaBounty reports widening H1 loss as FDA salmon approval remains elusive
SEAFOODNEWS.COM [SCOM] - August 15, 2014 -
Lonfon, Aqua Bounty Technologies Inc. (ABTX.LN) today posted a widened half loss, mainly due to increased spending on research and development and costs associated with preparation for listing on NASDAQ.
The company recorded a net loss of $3.5 million during the half year-ended June 30, compared with $2.1 million a year earlier.
The company said it continues to pursue the approval of its New Animal Drug Application for AquAdvantage Salmon, however, it has received no information on the status of FDA's finalization of approval of the application.
The company said it is renegotiating the lease for its farm site in Panama...
To Read Full Story Login Below.